<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00039052</url>
  </required_header>
  <id_info>
    <org_study_id>NBI-3001-ST-0101</org_study_id>
    <secondary_id>CDR0000069228</secondary_id>
    <secondary_id>UARIZ-HSC-01196</secondary_id>
    <secondary_id>UCLA-0108085</secondary_id>
    <secondary_id>NCI-V02-1692</secondary_id>
    <nct_id>NCT00039052</nct_id>
  </id_info>
  <brief_title>Intravenous Interleukin-4 PE38KDEL Cytotoxin in Treating Patients With Recurrent or Metastatic Kidney Cancer, Non-Small Cell Lung Cancer, or Breast Cancer</brief_title>
  <official_title>An Open Label, Multiple-Dose, Sequential Dose-Escalation Study of NBI-3001 in Patients With Recurrent or Unresponsive Solid Tumors Known to Over-Express IL-4 Receptors</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Neurocrine Biosciences</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>National Cancer Institute (NCI)</source>
  <brief_summary>
    <textblock>
      RATIONALE: Interleukin-4 PE38KDEL cytotoxin may be able to deliver cancer-killing substances&#xD;
      directly to solid tumor cells.&#xD;
&#xD;
      PURPOSE: Phase I trial to study the effectiveness of intravenous interleukin-4 PE38KDEL&#xD;
      cytotoxin in treating patients who have recurrent or metastatic kidney cancer, non-small cell&#xD;
      lung cancer, or breast cancer that has not responded to previous treatment.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES:&#xD;
&#xD;
        -  Determine the maximum tolerated dose of interleukin-4 PE38KDEL cytotoxin in patients&#xD;
           with recurrent or unresponsive, metastatic renal cell, non-small cell lung, or breast&#xD;
           cancer that overexpresses interleukin-4 receptors.&#xD;
&#xD;
        -  Determine the qualitative and quantitative toxic effects of this drug, including the&#xD;
           duration and intensity of these toxic effects, in these patients.&#xD;
&#xD;
        -  Determine the pharmacokinetic behavior of this drug in these patients.&#xD;
&#xD;
        -  Determine the antibody response (if any) in patients treated with this drug.&#xD;
&#xD;
        -  Determine, in a preliminary manner, the antitumor activity of this drug in these&#xD;
           patients.&#xD;
&#xD;
      OUTLINE: This is a dose-escalation, multicenter study.&#xD;
&#xD;
      Patients receive interleukin-4 PE38KDEL cytotoxin (NBI-3001) IV over 10 minutes once daily on&#xD;
      days 1-5. Treatment repeats every 28 days in the absence of disease progression, unacceptable&#xD;
      toxicity, or detection of neutralizing antibodies.&#xD;
&#xD;
      Cohorts of 3-6 patients receive escalating doses of NBI-3001 until the maximum tolerated dose&#xD;
      (MTD) is determined. The MTD is defined as the dose preceding that at which at least 2 of 3&#xD;
      or 2 of 6 patients experience dose-limiting toxicity.&#xD;
&#xD;
      PROJECTED ACCRUAL: A maximum of 36 patients will be accrued for this study.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>January 2002</start_date>
  <completion_date type="Actual">July 2008</completion_date>
  <primary_completion_date type="Actual">May 2003</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <primary_purpose>Treatment</primary_purpose>
  </study_design_info>
  <condition>Breast Cancer</condition>
  <condition>Kidney Cancer</condition>
  <condition>Lung Cancer</condition>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>interleukin-4 PE38KDEL cytotoxin</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        DISEASE CHARACTERISTICS:&#xD;
&#xD;
          -  Histologically confirmed recurrent or unresponsive, metastatic renal cell, non-small&#xD;
             cell lung, or breast cancer that has been treated previously with standard surgery,&#xD;
             radiotherapy, chemotherapy, or immunotherapy or for which no available treatment&#xD;
             options currently exist&#xD;
&#xD;
          -  Confirmed overexpression of interleukin-4 receptors&#xD;
&#xD;
          -  Measurable disease (lesions greater than 10 mm by CT scan) OR&#xD;
&#xD;
          -  Evaluable disease&#xD;
&#xD;
          -  No prior or concurrent clinically significant brain metastases&#xD;
&#xD;
          -  Hormone receptor status:&#xD;
&#xD;
               -  Not specified&#xD;
&#xD;
        PATIENT CHARACTERISTICS:&#xD;
&#xD;
        Age:&#xD;
&#xD;
          -  18 and over&#xD;
&#xD;
        Sex:&#xD;
&#xD;
          -  Male or female&#xD;
&#xD;
        Menopausal status:&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Performance status:&#xD;
&#xD;
          -  Karnofsky 70-100%&#xD;
&#xD;
        Life expectancy:&#xD;
&#xD;
          -  More than 12 weeks&#xD;
&#xD;
        Hematopoietic:&#xD;
&#xD;
          -  Absolute neutrophil count at least 1,500/mm^3&#xD;
&#xD;
          -  Platelet count at least 100,000/mm^3&#xD;
&#xD;
        Hepatic:&#xD;
&#xD;
          -  Bilirubin no greater than 1.5 times upper limit of normal (ULN)&#xD;
&#xD;
          -  Transaminases no greater than 1.5 times ULN&#xD;
&#xD;
          -  Albumin at least 2.5 g/dL&#xD;
&#xD;
          -  Hepatitis B surface antigen negative&#xD;
&#xD;
          -  Hepatitis C antibody negative&#xD;
&#xD;
          -  No prior or concurrent hepatic disease (e.g., hepatitis or alcoholic liver disease)&#xD;
&#xD;
        Renal:&#xD;
&#xD;
          -  Creatinine no greater than 2.0 mg/dL&#xD;
&#xD;
        Cardiovascular:&#xD;
&#xD;
          -  See Surgery&#xD;
&#xD;
          -  Electrocardiogram normal&#xD;
&#xD;
          -  MUGA scan normal&#xD;
&#xD;
          -  No congestive heart failure&#xD;
&#xD;
          -  No cardiac arrhythmia requiring treatment&#xD;
&#xD;
          -  No myocardial infarction&#xD;
&#xD;
          -  No clinical evidence of coronary artery disease (unless there is a cardiac evaluation&#xD;
             and evidence of adequate coronary function by a stress test or angiography)&#xD;
&#xD;
        Other:&#xD;
&#xD;
          -  Not pregnant or nursing&#xD;
&#xD;
          -  Negative pregnancy test&#xD;
&#xD;
          -  Fertile patients must use effective contraception for 4 weeks before, during, and for&#xD;
             at least 3 months after study&#xD;
&#xD;
          -  No concurrent underlying medical condition that would preclude study or cannot be&#xD;
             controlled&#xD;
&#xD;
          -  No active infection&#xD;
&#xD;
        PRIOR CONCURRENT THERAPY:&#xD;
&#xD;
        Biologic therapy:&#xD;
&#xD;
          -  See Disease Characteristics&#xD;
&#xD;
        Chemotherapy:&#xD;
&#xD;
          -  See Disease Characteristics&#xD;
&#xD;
          -  At least 4 weeks since prior chemotherapy (6 weeks for nitrosoureas or mitomycin)&#xD;
&#xD;
        Endocrine therapy:&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Radiotherapy:&#xD;
&#xD;
          -  See Disease Characteristics&#xD;
&#xD;
          -  At least 4 weeks since prior radiotherapy&#xD;
&#xD;
        Surgery:&#xD;
&#xD;
          -  See Disease Characteristics&#xD;
&#xD;
          -  At least 1 year since prior surgery or angioplasty for coronary artery disease&#xD;
&#xD;
        Other:&#xD;
&#xD;
          -  At least 28 days since prior experimental drugs and recovered&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Henry Pan, MD, PhD</last_name>
    <role>Study Chair</role>
    <affiliation>Neurocrine Biosciences</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Arizona Cancer Center</name>
      <address>
        <city>Tucson</city>
        <state>Arizona</state>
        <zip>85724</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Jonsson Comprehensive Cancer Center, UCLA</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90095-5907</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>March 2003</verification_date>
  <study_first_submitted>June 6, 2002</study_first_submitted>
  <study_first_submitted_qc>January 26, 2003</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 27, 2003</study_first_posted>
  <last_update_submitted>July 17, 2013</last_update_submitted>
  <last_update_submitted_qc>July 17, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">July 18, 2013</last_update_posted>
  <keyword>stage IV breast cancer</keyword>
  <keyword>recurrent breast cancer</keyword>
  <keyword>recurrent non-small cell lung cancer</keyword>
  <keyword>stage IV renal cell cancer</keyword>
  <keyword>recurrent renal cell cancer</keyword>
  <keyword>stage IV non-small cell lung cancer</keyword>
  <keyword>male breast cancer</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Breast Neoplasms</mesh_term>
    <mesh_term>Lung Neoplasms</mesh_term>
    <mesh_term>Kidney Neoplasms</mesh_term>
    <mesh_term>Carcinoma, Renal Cell</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Interleukin-4</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

